Expansion of Overseas Production and Sales
First written in FY2016. 16 of 24 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-06.
1 other company's latest entry also says "Cited as achieved".
- 2026-08-06Cited as achievedEarnings presentation
「In liquid containers, the Malaysian subsidiary performed well on expanding demand in Asia.」
The liquid container business at the Malaysian subsidiary performed well against a backdrop of expanding demand in Asia. - FY2026AdvancedAnnual report
「The company plans to begin operations at a new sales base in India in fiscal 2026 and at a new production base in China in fiscal 2026, strengthening its competitiveness and earnings base in Asia.」
The company gave concrete form to a plan to expand its production and sales structure in Asia by combining a production base in Wuxi, China, with a sales base in India. - FY2026-H1AdvancedAnnual report
「At a board meeting held on 16 January 2025, the company resolved to establish a subsidiary in Wuxi, Jiangsu Province, China, to manufacture and sell CUBITAINER, a liquid container for commercial use. It established 賽諾世精密材料（無錫）有限公司 on 18 June of the same year. As a result, the number of subsidiaries in the group increased by 1.」
The company established a subsidiary in Wuxi, China, to manufacture and sell CUBITAINER, expanding its overseas production and sales structure. - FY2025AdvancedAnnual report
「Accelerating overseas expansion by improving the profitability of domestic pharmaceutical and medical packaging materials and strengthening production in Southeast Asia」
The company presented strengthened production in Southeast Asia and accelerated overseas expansion as specific business measures for expanding overseas production and sales. - FY2024RestatedAnnual report
「ZACROS MALAYSIA SDN.BHD. and Shenzhen Tengshen Technology Materials Co., Ltd. have been included in the scope of consolidation from the current consolidated fiscal year because their strategic importance as bases for the Asian and Chinese markets is expected to increase.」
The full-year report also confirmed the policy of consolidating the Malaysian and Chinese subsidiaries as strategic bases for the Asian and Chinese markets as part of the company's overseas expansion. - FY2024-Q3RestatedAnnual report
「ZACROS MALAYSIA SDN.BHD. has been included in the scope of consolidation since the first quarter of the current fiscal year. Shenzhen Tengshen Technology Materials Co., Ltd. (FS China Co.,Ltd.) has been included in the scope of consolidation since the first quarter of the current fiscal year.」
The inclusion of the Malaysian and Chinese subsidiaries in the scope of consolidation as strategic bases for the Asian and Chinese markets was reaffirmed. - FY2024-Q2RestatedAnnual report
「ZACROS MALAYSIA SDN.BHD. has been included in the scope of consolidation since the first quarter of the current fiscal year. Shenzhen Tengshen Technology Materials Co., Ltd. (FS China Co.,Ltd.) has also been included in the scope of consolidation since the first quarter of the current fiscal year.」
The inclusion of the Malaysian and Chinese subsidiaries in the scope of consolidation as strategic bases for the Asian and Chinese markets was reaffirmed. - FY2024-Q1AdvancedAnnual report
「ZACROS MALAYSIA SDN.BHD. has been included in the scope of consolidation since the first quarter of the current fiscal year. Shenzhen Tengshen Technology Materials Co., Ltd. (FS China Co.,Ltd.) has also been included in the scope of consolidation since the first quarter of the current fiscal year.」
Including the Malaysian and Chinese subsidiaries in the scope of consolidation as strategic bases for the Asian and Chinese markets gave concrete form to the framework for overseas operations. - FY2023AdvancedAnnual report
「Overseas subsidiaries posted substantial sales growth in pharmaceutical and medical packaging materials, while revenue also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products.」
The growth in sales of pharmaceutical and medical packaging materials and single-use bags at overseas subsidiaries was reflected in full-year results. - FY2023-Q2AdvancedAnnual report
「Overseas subsidiaries posted substantial sales growth in pharmaceutical and medical packaging materials, while revenue also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products.」
Strong growth in overseas subsidiaries' sales of pharmaceutical and medical packaging materials indicated growth in the Wellness business driven by overseas expansion. - FY2023-Q1AdvancedAnnual report
「The business as a whole reported higher revenue, mainly because sales of pharmaceutical and medical packaging materials rose substantially at overseas subsidiaries. As a result, revenue was ¥6,313 million, up 9.5% year on year.」
Strong growth in sales of pharmaceutical and medical packaging materials at overseas subsidiaries contributed to 9.5% year-on-year revenue growth in the Wellness business. - FY2021AdvancedAnnual report
「Strengthening overseas operations by accelerating the overseas rollout of new-function product lines, production technologies and quality assurance processes, and establishing a local-for-local business structure capable of responding accurately and promptly to the needs of each region.」
The company identified as specific challenges in its overseas operations the establishment of a local-for-local business structure that meets the needs of each region and the acceleration of the overseas rollout of new-function products, production technologies and quality assurance processes. - FY2020AdvancedAnnual report
「Expansion in Southeast Asia coordinated with domestic production bases, with a view to growth in emerging markets Expansion of high-end products with added functionality in Europe and the United States」
The company's overseas business policy was defined in concrete terms as a business challenge involving expansion in Southeast Asia, as well as expansion of high-end products with added functionality in Europe and the United States. - FY2019RestatedAnnual report
「Our Group conducts overseas activities, including the import and export of products and local production and sales overseas.」
The company reaffirmed its expansion of overseas activities, including imports and exports and local production and sales overseas. - FY2018AdvancedAnnual report
「Group revenue increased year on year in each business, owing to the inclusion throughout the period of results from the Indonesian subsidiary acquired by the Life Science business in the middle of the previous fiscal year, steady sales in both building materials and civil engineering-related products in the Construction Materials business, and growing demand, particularly for the core protective film products, in the Information Electronics business.」
Overseas expansion continued to contribute to consolidated results, including the Indonesian subsidiary's full-year contribution. - FY2018-Q3AdvancedAnnual report
「The performance of the Indonesian subsidiary acquired around the middle of last year in the Life Sciences business was reflected for the full period.」
The Indonesian subsidiary's performance was reflected for a period equivalent to a full fiscal year, increasing the contribution of overseas operations to results. - FY2018-Q2RestatedAnnual report
「ZACROS (HONG KONG) CO., LTD., previously an unconsolidated subsidiary, has been included in the scope of consolidation since the first quarter because of its growing strategic importance as a base for the Chinese and Asian markets.」
The policy of including the Hong Kong subsidiary in the scope of consolidation as a strategic base for the China and Asian markets was reaffirmed. - FY2018-Q1AdvancedAnnual report
「ZACROS (HONG KONG) CO., LTD., previously an unconsolidated subsidiary, has been included in the scope of consolidation since the first quarter of the current consolidated fiscal year because of its growing strategic importance as a base for the Chinese and Asian markets.」
The Hong Kong subsidiary was included in the scope of consolidation and positioned as a strategic base for the Chinese and Asian markets, giving more concrete form to the overseas expansion structure. - FY2017RestatedAnnual report
「Our Group conducts overseas activities, including the import and export of products and local production and sales overseas.」
The Group reiterated its overseas activities, including imports and exports, local overseas production and sales, as the foundation of the business. - FY2017-Q3AdvancedAnnual report
「Revenue from the Indonesian consolidated subsidiary newly included in the scope of consolidation for pharmaceutical and medical packaging materials was added, while expanded sales of refillable stand-up pouches for household packaging also contributed, resulting in higher revenue for the business as a whole.」
Revenue from the Indonesian consolidated subsidiary was added to consolidated results as part of the overseas business. - FY2017-Q1AdvancedAnnual report
「Through this acquisition of shares, we will combine our technologies to expand our packaging business in the Southeast Asian market, where future growth is expected, and accelerate our global expansion.」
In addition to the existing expansion of overseas production and sales, the company made concrete progress by acquiring a packaging business in Indonesia. - FY2016First statedAnnual report
「Our Group conducts overseas activities, including the import and export of products and local production and sales overseas.」
Overseas activities, including imports and exports, local overseas production and sales, form the foundation of the business.